Natixis Advisors LLC Raises Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Natixis Advisors LLC boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 24.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 63,651 shares of the medical equipment provider's stock after buying an additional 12,602 shares during the period. Natixis Advisors LLC's holdings in Zimmer Biomet were worth $6,871,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Gradient Investments LLC lifted its position in Zimmer Biomet by 17.3% during the 2nd quarter. Gradient Investments LLC now owns 130,350 shares of the medical equipment provider's stock valued at $14,147,000 after acquiring an additional 19,224 shares during the period. National Pension Service increased its stake in shares of Zimmer Biomet by 3.8% during the third quarter. National Pension Service now owns 369,547 shares of the medical equipment provider's stock valued at $39,893,000 after purchasing an additional 13,612 shares in the last quarter. Swedbank AB bought a new stake in shares of Zimmer Biomet in the 1st quarter worth approximately $2,740,000. River Global Investors LLP grew its stake in shares of Zimmer Biomet by 31.3% in the 3rd quarter. River Global Investors LLP now owns 21,084 shares of the medical equipment provider's stock worth $2,276,000 after buying an additional 5,030 shares during the last quarter. Finally, Border to Coast Pensions Partnership Ltd raised its stake in Zimmer Biomet by 4.5% during the third quarter. Border to Coast Pensions Partnership Ltd now owns 155,254 shares of the medical equipment provider's stock valued at $16,711,000 after buying an additional 6,623 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Performance

ZBH stock traded up $1.82 during midday trading on Friday, reaching $110.22. 2,014,834 shares of the company's stock traded hands, compared to its average volume of 1,500,077. The stock's 50-day moving average is $106.71 and its 200 day moving average is $109.85. The stock has a market cap of $21.94 billion, a P/E ratio of 20.61, a PEG ratio of 2.04 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52-week low of $101.47 and a 52-week high of $133.90. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts' consensus estimates of $1.74. The company had revenue of $1.82 billion for the quarter, compared to analysts' expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period last year, the firm earned $1.65 EPS. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date was Monday, September 30th. Zimmer Biomet's dividend payout ratio is 18.25%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Wolfe Research started coverage on Zimmer Biomet in a report on Tuesday, September 10th. They set a "peer perform" rating for the company. Robert W. Baird decreased their target price on shares of Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating for the company in a report on Thursday, August 8th. Canaccord Genuity Group cut their price target on shares of Zimmer Biomet from $120.00 to $115.00 and set a "hold" rating on the stock in a report on Tuesday, September 10th. Oppenheimer reduced their price target on shares of Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating for the company in a research report on Tuesday, October 15th. Finally, UBS Group lowered their price objective on Zimmer Biomet from $112.00 to $107.00 and set a "sell" rating on the stock in a research report on Thursday, August 8th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $123.22.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.